SVC112, an elongation inhibitor, significantly suppressed the expression of c-Myc, CCND1, and Sox2 in HNSCC cells and CSCs across in vitro, ex vivo, and in vivo models. When combined with cisplatin and radiation therapy, SVC112 further reduced tumor growth in vivo. Here, MYC is linked to head and neck squamous cell carcinoma.